FDA — authorised 12 May 2022
- Application: NDA215446
- Marketing authorisation holder: SHIONOGI
- Local brand name: RADICAVA ORS
- Indication: SUSPENSION — ORAL
- Status: approved
🇺🇸 Radicava ORS in United States
FDA authorised Radicava ORS on 12 May 2022
Marketing authorisation
Other Neurology approved in United States
Frequently asked questions
Is Radicava ORS approved in United States?
Yes. FDA authorised it on 12 May 2022.
Who is the marketing authorisation holder for Radicava ORS in United States?
SHIONOGI holds the US marketing authorisation.